High TROP2 by IHC was found to be associated with advanced stage in CRC, but lower stage in urothelial cancer and lower grade in breast cancer.41 Therefore, further studies should incorporate more detailed clinical data in evaluating the association of TACSTD2 levels with patient outcomes to corroborate our findings. This evidence concerns the gene TACSTD2 and breast cancer.